Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Innodata Inc (INOD) vs Merck & Co., Inc. (MRK) Price & Performance

Innodata IncTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Innodata Inc vs Merck & Co., Inc. — how do they compare? Innodata Inc trades at $61.5 (market cap $2.05B), while Merck & Co., Inc. trades at $133.35 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 157× Innodata Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Innodata Inc pays none. Which is the better fit depends on your goals.

INODMRK
Market Cap
$2.05B$321.77B
Sector
TechnologyHealth
52-Week High
$121.50$131.84
52-Week Low
$34.45$77.60
Enterprise Value
$1.80B$368.53B
Dividend Yield
2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Innodata Inc

INOD trades at $61.47, down 1.21% today, but maintains strong technical support at $60-$62 levels with bullish oscillators and mixed moving averages. The company demonstrates robust fundamental performance with 58% year-over-year revenue growth in Q2 2026, beating earnings estimates for three consecutive quarters, and expanding profit margins to 14.66%. Recent AI-driven business developments and strong analyst coverage support the positive momentum.

INOD presents a compelling growth opportunity with accelerating AI services demand and consistent earnings outperformance, though premium valuation metrics (P/E 48.6, P/S 6.8) warrant caution. Key risks include customer concentration and competitive pressures in the rapidly evolving AI sector. Analyst consensus remains bullish with a $130 price target representing 111% upside potential from current levels.

Merck & Co., Inc.

MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.

MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Innodata Inc

Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.

Read more on INOD

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK